BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...By KAren Tkach Tuzman, Senior Editor A SPAC for Point Biopharma Inc. and a series A round for Aktis...
...$73 million and Nordic Nanovector ASA (OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...16 and week 24, respectively, compared with placebo. Point raises $20M for radioligand pipeline, manufacturing Point Biopharma Inc....
...DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point Biopharma Inc. Redx...
Items per page:
1 - 2 of 2
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...By KAren Tkach Tuzman, Senior Editor A SPAC for Point Biopharma Inc. and a series A round for Aktis...
...$73 million and Nordic Nanovector ASA (OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...16 and week 24, respectively, compared with placebo. Point raises $20M for radioligand pipeline, manufacturing Point Biopharma Inc....
...DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point Biopharma Inc. Redx...
Items per page:
1 - 2 of 2